AU2021104942A4 - A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows - Google Patents
A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows Download PDFInfo
- Publication number
- AU2021104942A4 AU2021104942A4 AU2021104942A AU2021104942A AU2021104942A4 AU 2021104942 A4 AU2021104942 A4 AU 2021104942A4 AU 2021104942 A AU2021104942 A AU 2021104942A AU 2021104942 A AU2021104942 A AU 2021104942A AU 2021104942 A4 AU2021104942 A4 AU 2021104942A4
- Authority
- AU
- Australia
- Prior art keywords
- cows
- afterbirths
- retention
- treatment
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000283690 Bos taurus Species 0.000 title claims abstract description 52
- 230000014759 maintenance of location Effects 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 12
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 12
- 240000007890 Leonurus cardiaca Species 0.000 claims abstract description 12
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 12
- 210000000582 semen Anatomy 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims description 11
- 241000157835 Gardenia Species 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 235000013336 milk Nutrition 0.000 abstract description 9
- 239000008267 milk Substances 0.000 abstract description 9
- 210000004080 milk Anatomy 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 210000004072 lung Anatomy 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract description 3
- 238000007599 discharging Methods 0.000 abstract description 2
- 230000001850 reproductive effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 8
- 229940118019 malondialdehyde Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000004382 Amylase Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 238000004737 colorimetric analysis Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000012173 estrus Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000004145 Endometritis Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 208000010515 dystocia Diseases 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 102000018146 globin Human genes 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000153 Abnormal labour Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
The present invention discloses a traditional Chinese medicine composition for
the treatment of retention of afterbirths in cows, which comprises Motherwort,
Codonopsis pilosula, Plantaginis Semen, Gardenia and other traditional Chinese
medicine materials. In the present invention, Motherwort promotes blood circulation,
Codonopsis pilosula can invigorate, Plantaginis Semen helps to moisturize the lungs.
The combination of these various medicines not only has the effects of promoting
blood circulation and removing blood stasis, which is conducive to discharging the
cow's afterbirths, but also can effectively promote the recovery of the postpartum
reproductive function of cows. It is not resistant to drugs, so there are no harmful
substances left in the body and no side effects. Tests have proved that the afterbirth
can be discharged about 1 day after the medication, and the cured body indicators are
close to healthy cows. The milk production is very close to that of healthy cows and
there are no residual substances harmful to the human body.
- 1 -
Description
A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows
Technical Field The present invention relates to the technical field of traditional Chinese medicine for animal husbandry, in particular to a traditional Chinese medicine composition for the treatment of retention of afterbirths in cows.
Backgcircular Art Retention of afterbirths is a common disease in postpartum cows. It refers to the fact that cows fail to discharge the afterbirths completely 8-12 hours after the birth of the calves. Under normal circumstances, this disease is not life-threatening, but it will cause the cow's milk production to decrease. It can cause endometritis, delayed uterine recovery and uterine prolapse, which lead to delayed postpartum estrus, reduced breeding and conception rate and other diseases, seriously affecting the fertility of cows. Severe cases can cause sepsis and cause death of sick cows. The occurrence of retention of afterbirths in cows is mainly due to improper feeding and management in the late pregnancy, or stimulation by external adverse factors during delivery, which leads to abnormal endocrine activity of the body, abnormal labor rhythm and destruction of uterine contractions, thereby causing the disease. Generally speaking, cows are more likely to have retention of afterbirths in summer and autumn than in winter and spring; or as the birth order and month age at delivery increase, Cows also more likely to have retention of afterbirths; or all abnormal births, such as miscarriage, twins or stillbirths, etc. will cause a significant increase in the retention of afterbirths. The conservative treatment for retention of afterbirths is to use capsules to put antibacterial drugs between the uterine mucosa and the afterbirths to prevent the afterbirths from decay, and then wait for the afterbirths to discharge on its own. However, this method of treatment cannot actively separate the afterbirths from the cow, so it takes a long time and is inefficient. Therefore, the present invention adopts a new method that is safer and has a reliable therapeutic effect. In this trial, the traditional Chinese medicine "Yi Shen Powder" was used to treat cows suffering from retention of afterbirths, and the therapeutic effect and mechanism of action were studied.
Summary of the Invention
Therefore, based on the above background, the present invention provides a traditional Chinese medicinal composition for the treatment of retention of afterbirths in cows with safer treatment and better therapeutic effect. The technical scheme of the present invention is as follows: A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows, wherein it comprises the following raw materials: Motherwort, Codonopsis pilosula, Plantaginis Semen, Gardenia Further, it comprises the following raw materials in parts by weight: 80-200 parts of Motherwort, 80-200 parts of Codonopsis pilosula, 80-200 parts of Plantaginis Semen (wine stir-fried), 20-80 parts of Gardenia. Further, it comprises the following raw materials in parts by weight: 150 parts of Motherwort, 150 parts of Codonopsis pilosula, 150 parts of Plantaginis Semen (wine stir-fried), 50 parts of Gardenia. Further, when the traditional Chinese medicine composition of the present invention is used: After mixing the raw materials, they are pulverized into 100-mesh powder to be used as an oral agent. The oral agent can be a feed additive powder, a capsule, or a tablet. In the above-mentioned traditional Chinese medicine composition, Motherwort has the functions of promoting blood circulation, regulating menstruation, diuresis and swelling, contracting the uterus, eliminating fluid accumulation, etc., and is often used clinically to treat women with irregular menstruation, postpartum blood dizziness, blood stasis, abdominal pain, fetal leakage, dystocia, infertility and other diseases; Codonopsis pilosula has the effects of invigorating the spleen and lungs. It is often used to treat spleen and lung weakness, shortness of breath, heart palpitations, loose stools, coughing, internal heat and thirst; Plantaginis Semen has the effects of clearing heat and diuresis, oozing dampness, improving eyesight, expectorating, etc. It is often used to treat edema and swelling, hot shower astringent pain, diarrhea of heat and dampness, swelling and pain with red eyes, phlegm-heat cough and other diseases; Gardenia has the effects of purging fire and irritability, clearing heat and diuresis, cooling blood and detoxification. It is often used to treat fever, irritability, jaundice, red urine, bloody astringent pain, blood-heat vomiting, swelling and pain with red eyes, and fire sores. Compared with the prior art, the beneficial effects of the present invention are as
follows:
In the present invention, Motherwort promotes blood circulation, Codonopsis pilosula can invigorate, Plantaginis Semen helps to moisturize the lungs. The combination of these various medicines not only has the effects of promoting blood circulation and removing blood stasis, which is conducive to discharging the cow's afterbirths, but also can effectively promote the recovery of the postpartum reproductive function of cows. It is not resistant to drugs, so there are no harmful substances left in the body and no side effects. Tests have proved that the afterbirth can be discharged about 1 day after the medication, and the cured body indicators are close to healthy cows. The milk production is very close to that of healthy cows and there are no residual substances harmful to the human body.
Specific Embodiments of the Invention In order to make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative work shall fall within the protection scope of the present invention. Embodiment 1: A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows. One dose of the Chinese medicinal composition is made from the following raw materials in parts by weight: Motherwort 150g, Codonopsis pilosula 150g, Plantaginis Semen (wine stir-fried) 150g, Gardenia 50g. When it is used, the raw materials are mixed according to the amount, and then pulverized into 100-mesh powder, which is then used as a feed additive or taken orally with water. Embodiment 2: A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows. One dose of the Chinese medicinal composition is made from the following raw materials in parts by weight: Motherwort 200g, Codonopsis pilosula 100g, Plantaginis Semen (wine stir-fried) 100g, Gardenia 60g. When it is used, the raw materials are mixed according to the amount, and then pulverized into 100-mesh powder, which is then used as a feed additive or taken
orally with water. Embodiment 3: In order to verify the efficacy of the present invention, a control experiment was conducted. 1) Selection of experimental animals The experimental dairy farm of Hebei Agricultural University. Choose 10 cases each of 2-4 gestational ages Holstein Friesian cows with postpartum retention of afterbirths and postpartum healthy. The postpartum healthy cows were the control group. The criteria were: medium nutrition or above, smooth labor, natural delivery, and discharge of the aftermath within 8 hours. There were no complications before and after delivery, and the calves were healthy. The treatment group of cows with retention of afterbirths. Choose 10 cases 2-4 gestational ages Holstein Friesian cows with postpartum retention of afterbirths, Stir and feed the traditional Chinese medicine composition of Embodiment 1 with feed, 500g each time, twice a day. The standard of postpartum retention of afterbirths in cows: medium or poor nutrition, accompanied by dystocia, weakness of the uterus, tearing of the birth canal, etc. The aftermath cannot be completely discharged within 8 hours after delivery. 2) Experiment grouping and processing The treatment group of cows with retention of afterbirths was given the traditional Chinese medicine composition in Embodiment 1 immediately after 8 hours of calving. The cows in the treatment group and the healthy control group were collected blood from the jugular vein at 8, 12, and 16 hours postpartum. Heparin (301U/ml whole blood) was used for anticoagulation of blood samples, take 4ml whole blood to measure the hemorheological indicator, the remaining blood is centrifuged at 3000r/min for 10min to separate the plasma and stored in the refrigerator at -20 °C to test the nitric oxide, oxygen free radicals and biochemical
indicators. 3) Indicators and measurement methods ( Indicator of hemorheological
Whole blood specific viscosity (b): horizontal capillary measurement method, the instrument is a lang-100 capillary viscometer produced by Shanghai Medical University, the test temperature is 37C, the reference fluid is normal saline, and the
shear rate is ab20S-1 (low shear rate) and ab80S-1 (high shear rate). Hematocrit (PVC): Measured by wintrobe hematocrit tube method, rotating speed is 3000r/min, time is 30min. The calculation formula of whole blood reduction specific viscosity (r): qr--(qb 1)/pcv. This experiment measured the whole blood specific viscosity with low shear rate and high shear rate. Therefore, the reduced specific viscosity of whole blood with two shear rates of low shear (qr2O-1) and high shear (qr80-1) was calculated. Red blood cell aggregation index (AI) calculation method: Red blood cell aggregation index = whole blood low shear specific viscosity/ whole blood high shear specific viscosity. Plasma specific viscosity (p): vertical capillary measurement method, the instrument is same as in the whole blood specific viscosity, anticoagulant blood is centrifuged at 3000r/min for 10 minutes, and plasma is taken for measurement. Total protein (TP) colorimetry: The instrument is a 722 spectrophotometer, and the kit was purchased from Beijing Bonding Bioengineering Co., Ltd. Determined according to the method specified in the kit. Fibrinogen (FG) colorimetry: The instrument is a 722 spectrophotometer, and the kit was purchased from Beijing Bonding Biological Engineering Co., Ltd. Determined according to the method specified in the kit. Albumin (ALB) colorimetry: The instrument is a 722 spectrophotometer, and the kit was purchased from Beijing Bonding Biological Engineering Co., Ltd. Determined according to the method specified in the kit. Globin calculation method: globulin = total protein-fibrinogen-albumin Hemoglobin (Hb) colorimetry: The instrument is a 722 spectrophotometer, and the kit was purchased from Beijing Bonding Biological Engineering Co., Ltd. Determined according to the method specified in the kit. @Determination of Nitric Oxide
Nitric oxide (NO): Measured by nitrate reductase method, the kit was purchased from Nanjing Jiancheng Institute of Bioengineering, and determined according to the method specified in the kit. @The main indicators of oxygen free radicals
Glutathione peroxidase (GSH-Px): Measured by dithiodinitrobenzoic acid method. The instrument is a 722 spectrophotometer, and the kit was purchased from
Nanjing Jiancheng Institute of Bioengineering, and determined according to the method specified in the kit. Malondialdehyde (MDA): Measured by thiobarbituric acid method. The instrument is a 722 spectrophotometer, and the kit was purchased from Nanjing Jiancheng Institute of Bioengineering, and determined according to the method specified in the kit. @Observation of main clinical indicators and milk production
Observe the changes in the time of afterbirth discharge, lochia discharge, endometrial morbidity, the time of first estrus, milk production, etc. @9Biostatistics method
The detection and observation data are analyzed using spss20.O software. 4) Results
QThe main indicators of hemorheology are determined in Table 1. Table 1: Comparison of determination results of main hemorrheological indicators between the treatment group of cows with retention of afterbirths and the control group of healthy postpartum cows
Group Postpartum rib80s-' ib20s-1 ir80- rir20-1 Hp PCV Al /h (mpas) (mpas) (mpas) (mpas) (mpas) (%)
8 4.38+0.07 5.24±0.41 10.970.82 13.76+3.66 1.780.89 30.84+30.85 1.20+0.04
12 4.04+0.09 4.55+0.18 9.89+1.46 11.56+2.93 1.720.62 30.74+10.69 1.130.21
16 3.92+0.09 4.36+0.11 9.30+0.83 10.70+0.96 1.710.83 31.41+11.25 1.110.01
8 4 . 7 5 ±0. 2 6 a** 5 .7 9 ±0. 6 3A**11.251.61l 14 .38±2. 3 3 *2 .090.01a**33.312.35a*1.220. 12B*
12 4 .2 6 0. 1 1 4 .7 9 ±0. 15 B 1 0 1 9 ± 1 0 1 b1 2 8 6 ±2 8 1B 1 9 1 0 0 1 b 3 2 0 0 ±0 9 8 b 1 1 3 0 0 2 AA
16 3 .9 3 ±0. 10 4 .3 5 ±0. 14 B 9 .5 6 ±1. 7 3b 10 .5 9 ±2. 9 1B 1 8 2 0 0 1 b 3 1 6 4 ±2 40 b 1 1 1 0 0 2 A
See Table 1, the results show that the value of qb80s-1 in the treatment group shows a gradual decrease, and the data at 8h is significantly higher than that at 12h and 16h, P<0.05, and the value at 12h and 16h is close to that of the control group, P> 0.05. The value of qb20s-1 in the treatment group showed a gradually decreasing trend, and the value of 8h was extremely significantly higher than that of 12h and 16h, P<0.01. In comparison between the two groups, the 8h value of the treatment group was significantly higher than that of the control group, P<0.01; its 12h and 16h values were close to those of the control group, P>0.05.
The value of qr80s-1 in the treatment group showed a gradually decreasing trend, and the value of 8h was significantly higher than that of 12h and 16h, P<0.05. In comparison between the two groups, the difference between the treatment group and the control group was not significant, P>0.05. The value of gr2Os-1 in the treatment group showed a gradually decreasing trend, and the value of 8h was significantly higher than that of 12h and 16h, P<0.05. In comparison between the two groups, the 8h value of the treatment group was significantly higher than that of the control group, P<0.05, and the 12h and 16h values of the two groups were not significantly different. The Hp value of the treatment group showed a gradually decreasing trend, and the value of 8h was significantly higher than that of 12h and 16h, P<0.05. In comparison between the two groups, the 8h value of the treatment group was significantly higher than that of the control group, P<0.01, and the 12h and 16h values were close to those of the control group, P>0.05. The PCV value of the treatment group showed a gradual decrease, and the value of 8h was significantly higher than that of 12h and 16h, P<0.05. In comparison between the two groups, the 8h value of the treatment group was significantly higher than that of the control group, P<0.05, and its 12h and 16h values were close to those of the control group, P>0.05. The value of Al in the treatment group showed a gradual decrease, the value of 8h was significantly higher than that of 12h and 16h, P<0.05. In comparison between the two groups, the 8h value of the treatment group was significantly higher than that of the control group, P<0.05, and the 12h and 16h values were close to those of the control group, P>0.05. @The results of determination of protein content and clotting time in blood are
shown in Table 2. Table 2: Comparison of protein content and clotting time in blood determination results between the treatment group of cows with retention of afterbirths and the control group of healthy postpartum cows
Group Postpartum TP (g/L) FG (g/L) ALB (g/L) Globin (g/L) ib (g/L) CT (min)
8 64.53±16.06 7.04+0.17 23.56+0.22 33.73+6.28 98.53+30.60 7.65+0.05
12 66.38+18.74 6.67+0.18 24.66+1.44 35.06+2.91 92.23+13.82 8.57+0.03
16 67.83+7.76 6.36+0.26 25.39+1.48 36.08+4.14 94.23+21.17 9.03+0.59
8 54.9610.296 * 7.11 2 *7.1.61a**7.291.05B*
12 62.38±17.98a 7 .0 1 ±0. 9 2 ' 2 4 . 1 3 ±2. 3 6 ab 3 1 .2 4 ±6.2 1 a 9 6 .0 0 ±8. 7 9 ' 8 .8 4 ±0.2 1A
16 65.80±7.56a 6 .6 8 ±0. 4 0 ' 25.90±0.87a 33.23±5.10a 9 4 .9 3 ±2 1 . 6 1 ' 9 .5 9 ±0.4 4A
@Results of nitric oxide determination (see Table 3) Table 3: Comparison of nitric oxide determination results between the treatment group of cows
with retention of afterbirths and the control group of healthy postpartum cows
Postpartum (h) 8 12 16
Control group (n=10) 26.16±1.18 25.22±1.06 24.14±0.61
Treatment group (n=10) 30.89+3.26a* 27.54±1. 5 0 ' 25.12+ 2 .50'
Note: The unit is imol/L
The results of the measured values in Table 3 showed that the NO in the treatment group showed a gradual decrease, and the NO value at 8h was significantly higher than that at 12h and 16h, P<0.05. In comparison between the two groups, the 8h value of the treatment group was significantly higher than that of the control group, P<0.05, and its 12h and 16h values were close to those of the control group, P>0.05.
@4Determination results of main indicators of oxygen free radicals (see Table 4) Table 4: Comparison of determination results of GSH-Px activity and MDA activity between the
treatment group of cows with retention of afterbirths and the control group of healthy postpartum
cows
Experiment Control group (n=10) Treatment group (n=10) group
Postpartum (h) 8 12 16 8 12 16
GSH-Px 145.96± 150.34+ 152.36 ± 141.86± 148.92± 152.25+ (Vitality unit) 10.248 32.66 30.44 14.75B* 5.82Ab 9.96Aa
MDA content 4.08± 3.67± 3.64± 5.34± 4.00± 3.79+ (nmol/ml) 0.08 0.11 0.10 1.6 8 A* 1.90B 1.0gB The results in Table 4 show that the GSH-Px of the treatment group showed a gradual increase trend, and the GSH-Px value of 8h was significantly lower than that of 12h and 16h, P<0.01. In comparison between the two groups, the GSH-Px of the treatment group at 8h was significantly lower than that of the control group, P<0.05, and the GSH-Px of 2h and 16h was close to that of the control group, P>0.05. The MDA of the treatment group in Table 4 showed a gradual decrease trend, and the MDA of 8h was significantly higher than that of 12h and 16h, P<0.01. In comparison between the two groups, the 8h MDA of the treatment group was
significantly higher than that of the control group, P<0.05, and the MDA of 12h and 16h was close to that of the control group, P>0.05. (9Determination results of other biochemical indicators (see Table 5) Table 5: Comparison of blood glucose and amylase activity determination results between the treatment group of cows with retention of afterbirths and the control group of healthy postpartum cows Experiment Control group (n=10) Treatment group (n=10) group Postpartum 8 12 16 8 12 16 (n=9)
Glu 57.71± 63.65± 65.85± 50.88± 59.32+ 64.25± (g/dl) 8.59 2.99 3.38 1.18b* 1.97a 4.52a
a-Amylase 76.69± 77.41+ 79.68± 68.31+ 75.47± 80.61+ (Somogyi unit/dl) 2.69 4.59 4.25 1.65A* 6. 9 7B 3.B The results in Table 5 showed that the GLU of the treatment group showed an increasing trend. The GLU of 8h was significantly lower than that of 12h and 16h, P<0.05. In comparison between the two groups, the GLU of the treatment group at 8h was significantly lower than that of the control group, P<0.05, and the GLU at 12h and 16h was close to that of the control group, P>0.05. The amylase activity of the treatment group showed a gradual increase trend, and its 8h amylase activity was significantly lower than its 12h and 16h, P<0.01. In comparison between the two groups, the amylase activity of the treatment group at 8h was significantly lower than that of the control group, P<0.05, and its 12h and 16h were close to those of the control group, P>0.05.
@DMain clinical indicators and milk production (see Table 6 and Table 7) Table 6: Comparison of observation results of main clinical indicators between the treatment group of cows with retention of afterbirths and the control group of healthy postpartum cows
Afterbirth Lochia discharge Incidence of endometritis Time of first estrus after Group N retention rate(%) time (d) (%) delivery (d)
Control 10 0 5 14.40 3.25 33.33 0. 6 0 l 8 .9 0 group
Treatment 10 11.11 15.25i3.12 22.22 49.25il2.30 group
Comparison >0.05 >0.05 >0.05 >0.05
The results in Table 6 show that the time to lochia discharge, endometrial morbidity, and time of first estrus after delivery in the treatment group were not
significantly different from those in the control group (P>0.05). Table 7: Comparison of milk production determination results between the treatment group of cows with retention of afterbirths and the control group of healthy postpartum cows Postpartum (d) 15 30 45 60 90
Control group (n=10) 27.28+10.25 33.62+9.68 39.96+11.68 43.49+12.01 40.78+9.25
Treatment group 27.96+9.24A 35.31+12.35B 41.26±9.21 C 46.24±12.94C 41 6 9 ±10.2 8 c (n- 10) Note: The unit is kg/d. The results in Table 7 show that the postpartum milk production of the two groups of cows gradually increased, reaching the peak milk production period around days. There was no significant difference between the treatment group and the control group, P>0.05. The experimental data of Embodiment 3 all show that the traditional Chinese medicine composition of the present invention can not only effectively treat the cows with retention of afterbirths, but also the body indicators are close to healthy cows after the treatment. The milk production is very close to that before treatment and no side effects. Although the embodiments of the present invention have been shown and described, those of ordinary skill in the art can understand that various changes, modifications, substitutions and modifications can be made to these embodiments without departing from the principle and purpose of the present invention. The scope of the present invention is defined by the claims and their equivalents.
Claims (3)
1. A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows, wherein it comprises the following raw materials: Motherwort, Codonopsis pilosula, Plantaginis Semen, Gardenia
2. A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows according to claim 1, wherein it comprises the following raw materials in parts by weight: 80-200 parts of Motherwort, 80-200 parts of Codonopsis pilosula, 80-200 parts of Plantaginis Semen (wine stir-fried), 20-80 parts of Gardenia.
3. A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows according to claim 2, wherein it comprises the following raw materials in parts by weight: 150 parts of Motherwort, 150 parts of Codonopsis pilosula, 150 parts of Plantaginis Semen (wine stir-fried), 50 parts of Gardenia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021104942A AU2021104942A4 (en) | 2021-08-04 | 2021-08-04 | A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021104942A AU2021104942A4 (en) | 2021-08-04 | 2021-08-04 | A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021104942A4 true AU2021104942A4 (en) | 2021-10-21 |
Family
ID=78177048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021104942A Ceased AU2021104942A4 (en) | 2021-08-04 | 2021-08-04 | A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2021104942A4 (en) |
-
2021
- 2021-08-04 AU AU2021104942A patent/AU2021104942A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Whalley et al. | Oxytocin and water intoxication | |
| Rosenheim et al. | Unilateral renal ischaemia due to compression of a renal artery by a phaeochromocytoma | |
| CN102836186B (en) | Tibetan medicine for treating haemorrhoids and preparation method thereof | |
| AU2021104942A4 (en) | A traditional Chinese medicine composition for the treatment of retention of afterbirths in cows | |
| Rigby et al. | Use of prostaglandin E2 to ripen the cervix of the mare prior to induction of parturition | |
| CN105943651B (en) | A kind of Chinese medicine composition that treating premature ovarian failure and its application | |
| CN102145162B (en) | Injection of medicine for treating premature delivery | |
| CN102370795B (en) | Self-heated traditional Chinese medicine (TCM) emplastrum for treating primary dysmenorrhea | |
| CN113521175A (en) | New use of a Chinese medicinal composition in preparing medicine for treating male teratospermia | |
| Potla et al. | Pelvic Congestion Syndrome in a Postmenopausal Female | |
| CN102139010B (en) | Traditional Chinese medicine for treating postabortal colporrhagia | |
| CN113018367B (en) | Traditional Chinese medicine composition for treating thin endometrial hypomenorrhea and preparation method and application thereof | |
| Plass et al. | Hemorrhagic encephalitis (neoarsphenamine) in obstetric patients | |
| CA2700990C (en) | Uterine stimulant sticks | |
| Ehrenfest | Menstruation and its disorders: A critical review of the literature from 1933 to 1936 inclusive | |
| CN112656867B (en) | Traditional Chinese medicine composition for treating abnormal uterine bleeding and preparation method thereof | |
| CN116077564B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hemorrhoids | |
| CN112870277B (en) | Traditional Chinese medicine composition for preventing and treating recurrent abortion | |
| CN107648243A (en) | Purposes of the Quzhazhigan in the medicine of cerebral hemorrhage caused by rtPA thromboembolism treatments after preparing treatment cerebral hemorrhage or reduction cerebral ischemia | |
| Aranakalle | Effect of Dadimadi Ghrita in Garbhini Pandu (anaemia in pregnancy) | |
| Henderson et al. | Hematuria in a case of sickle cell disease | |
| CN104997797B (en) | A kind of pharmaceutical composition for treating infant eczema | |
| RU2650649C2 (en) | Veterinary medicinal product with anti-inflammatory, antipruritic and regenerative action in inflammatory skin diseases | |
| RU2270011C2 (en) | Method for treatment of fetoplacental insufficiency | |
| CN100525808C (en) | Chinese traditional medicine compound took orally for treating metropathia hemorrhagica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |